Blue Cross v. SmithKline Beecham Clinical Laboratories, Inc.

62 F. Supp. 2d 544, 1998 U.S. Dist. LEXIS 20942, 1998 WL 1094868
CourtDistrict Court, D. Connecticut
DecidedJune 11, 1998
DocketCiv. 3:97CV1795 AVC, Civ 3:97CV1835 AVC and Civ. 3:97CV2052 AVC
StatusPublished
Cited by7 cases

This text of 62 F. Supp. 2d 544 (Blue Cross v. SmithKline Beecham Clinical Laboratories, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Connecticut primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Blue Cross v. SmithKline Beecham Clinical Laboratories, Inc., 62 F. Supp. 2d 544, 1998 U.S. Dist. LEXIS 20942, 1998 WL 1094868 (D. Conn. 1998).

Opinion

RULING ON THE DEFENDANT’S MOTIONS TO DISMISS

COYELLO, Chief Judge.

This is an action for legal and equitable relief in which the plaintiffs, thirty-seven health care insurers and payers for health care services and two putative class actions, claim that the defendant, SmithKline Beecham Clinical Laboratories, Inc. (“SBCL”), engaged in, inter alia, fraudulent billing practices. 1 The amended com *548 plaint alleges causes of action under the Racketeer Influenced and Corrupt Organizations Act, 18 U.S.C. § 1961 et seq. (“RICO”), the Employee Retirement Income Security Act, 29 U.S.C. § 1001 et seq. (“ERISA”), and under common law tenets sounding in unjust enrichment and restitution. The defendant now moves to dismiss the amended complaint in its entirety under Fed.R.Civ.P. 12(b)(6) and 28 U.S.C. § 1367.

The issues presented are as follows: 1) whether the amended complaint alleges with sufficient particularity a RICO enterprise and, if so, whether the “person” and the “enterprise” are sufficiently distinct under 18 U.S.C. § 1962(c); 2) whether the plaintiffs are fiduciaries within the meaning of ERISA and, thus, have standing to proceed under ERISA; and 3) whether the court should recognize a federal common law cause of action concerning unjust enrichment and/or restitution in favor of non-fiduciaries under ERISA.

For the reasons hereinafter set forth, the court concludes that: 1) the amended complaint fails to allege with sufficient particularity a RICO enterprise, and the “person” and the “enterprise” are not sufficiently distinct under 18 U.S.C. § 1961(c); 2) based upon the pleadings as they currently exist, the court is unable to determine whether any of the plaintiffs are “fiduciaries” within the meaning of ERISA to establish standing; and 3) the court declines to recognize a federal common law cause of action for unjust enrichment in favor of non-fiduciaries. Accordingly, the defendant’s motions to dismiss the Blue Cross amended complaint (document no. 55), the Clark amended complaint (document # 113), and the Watkins complaint (document no. 57) are hereby GRANTED. The plaintiffs are granted leave to replead their RICO and ERISA causes of action consistent with this ruling.

FACTS

The record discloses that the plaintiffs are thirty-seven health insurers and payers for health care services and two putative class actions. 2 SBCL is a subsidiary of SmithKline Beecham pic, a British corporation and incorporated in the state of Delaware. SBCL owns and operates one *549 of the nation’s largest chains of clinical laboratories.

The Blue Cross amended complaint 3 and the RICO Case Statement 4 alleges the following: “Over the last decade, SBCL defrauded both private and public health care payers in connection with the performance and billing of laboratory tests through the nationwide manipulation of the process by which third-party payers pay for medical services. Through false representations, misleading marketing, and simple false billing, SBCL manipulated physician ordering practices and exploited third party payers’ dependence on those ordering practices in the payment of the claims.”

At the core of this alleged fraudulent scheme is what the plaintiffs refer to as a nationwide “Billing Network.” The scheme exploited the health care payment system in five main ways:

1) SBCL billed plaintiffs for tests that physicians did not order or intend to order and billed for tests that it had led physicians to believe would not result in separate charges (“Add-ons”);

2) SBCL billed plaintiffs separately for expensive constituents of test panels that should have been billed at a single composite rate (“unbundling”);

3) SBCL billed plaintiffs twice for the same procedure (“double billing”);

4) SBCL performed and billed plaintiffs for more expensive tests than ordered (“upcoding”), and in some cases performed; and

5) SBCL inserted fabricated diagnosis codes to obtain reimbursement from third party payers (“code jamming”).

The plaintiffs claim that, through this scheme, SBCL effectively substituted its own financially self-interested judgment for the informed, clinical judgment of physicians. The plaintiffs further claim that SBCL forced its scheme on unsuspecting physicians by offering institutional incentives and kickbacks. The incentives included test discounts, hiring physician family members, computer equipment, refrigerators, free phlebotomists’ services, office draw sites and other free services, such as writing off STAT (urgent) services which were then billed to third party payers.

STANDARD

A motion to dismiss pursuant to Fed. R.Civ.P. 12(b)(6) involves a determination as to whether the plaintiff has stated a claim upon which relief can be granted. Fischman v. Blue Cross Blue Shield, 755 F.Supp. 528, 530 (D.Conn.1990). The motion must be decided solely on the facts alleged. Goldman v. Belden, 754 F.2d 1059, 1065 (2d Cir.1985). In deciding a motion to dismiss, a court must assume all factual allegations in the complaint to be true and must draw reasonable references in favor of the non-moving party. Scheuer v. Rhodes, 416 U.S. 232, 94 S.Ct. 1683, 1686, 40 L.Ed.2d 90 (1974). “When determining the sufficiency of plaintiffs’ claim for Rule 12(b)(6) purposes, consideration is limited to the factual allegations in [the] plaintiffs’ amended complaint, which are accepted as true, to documents attached to the complaint as an exhibit or incorporated in it by reference, to matters of which judicial notice may be taken, or to documents either in plaintiffs’ possession or of which plaintiffs had knowledge and relied on in bringing the suit.” Brass v. American Film Technologies, Inc., 987 F.2d 142, 150 (2d Cir.1993) (citations omitted). Such motion must be granted only where no set of facts consistent with the allegations *550 could be proven which would entitle the plaintiff to relief. Conley v. Gibson, 355 U.S.

Related

Craig Outdoor v. Wally Kelly
Eighth Circuit, 2008
In Re Lupron® Marketing & Sales Practices Litigation
295 F. Supp. 2d 148 (D. Massachusetts, 2003)
In Re Pharmaceutical Industry Average Wholesale Price Litigation
263 F. Supp. 2d 172 (D. Massachusetts, 2003)
Stewart v. Nynex Corp.
78 F. Supp. 2d 172 (S.D. New York, 1999)

Cite This Page — Counsel Stack

Bluebook (online)
62 F. Supp. 2d 544, 1998 U.S. Dist. LEXIS 20942, 1998 WL 1094868, Counsel Stack Legal Research, https://law.counselstack.com/opinion/blue-cross-v-smithkline-beecham-clinical-laboratories-inc-ctd-1998.